Brookline Cap M Estimates IceCure Medical Q1 Earnings

IceCure Medical Ltd. (NASDAQ:ICCM) – Stock analysts at Brookline Cap M issued their Q1 2026 earnings per share (EPS) estimates for IceCure Medical in a report issued on Tuesday, March 17th. Brookline Cap M analyst K. Dolliver anticipates that the company will post earnings of ($0.03) per share for the quarter. The consensus estimate for IceCure Medical’s current full-year earnings is ($0.28) per share. Brookline Cap M also issued estimates for IceCure Medical’s Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.03) EPS and FY2030 earnings at $0.22 EPS.

IceCure Medical (NASDAQ:ICCM) last issued its quarterly earnings data on Tuesday, March 17th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). IceCure Medical had a negative net margin of 445.61% and a negative return on equity of 248.23%. The company had revenue of $1.28 million for the quarter, compared to analyst estimates of $1.30 million.

A number of other equities analysts have also commented on ICCM. Weiss Ratings reissued a “sell (e+)” rating on shares of IceCure Medical in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of IceCure Medical from a “sell” rating to a “hold” rating in a research note on Saturday, February 7th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, IceCure Medical currently has a consensus rating of “Hold” and an average target price of $2.64.

IceCure Medical Stock Down 9.8%

Shares of IceCure Medical stock opened at $0.60 on Thursday. The stock has a market capitalization of $41.23 million, a P/E ratio of -2.50 and a beta of 0.29. The stock has a 50 day moving average price of $0.63 and a two-hundred day moving average price of $0.75. IceCure Medical has a 12-month low of $0.54 and a 12-month high of $1.50.

Hedge Funds Weigh In On IceCure Medical

Large investors have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new stake in IceCure Medical in the 4th quarter worth $39,000. Concurrent Investment Advisors LLC acquired a new position in shares of IceCure Medical during the fourth quarter valued at about $48,000. Finally, Jane Street Group LLC acquired a new position in shares of IceCure Medical during the fourth quarter valued at about $67,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.